2. Academic Validation
  3. Chloroethylnitrosourea analogue HJ03 overcomes temozolomide resistance of glioblastoma in mice through induction of ferroptosis and apoptosis

Chloroethylnitrosourea analogue HJ03 overcomes temozolomide resistance of glioblastoma in mice through induction of ferroptosis and apoptosis

  • Acta Pharmacol Sin. 2026 Mar 2. doi: 10.1038/s41401-025-01744-y.
Heng Yang # 1,  Yi Cao # 1,  Wei Zhao # 1,  Ying-Fan Wen 1,  Yan Wu 1,  Ting Wang 2,  Li-Zhi Zhu 3 4,  Yong-Dong Zou 5,  Bao-Min Xi 6,  Duo Zheng 7
Affiliations

Affiliations

  • 1 Guangdong Provincial Key Laboratory of Genome Stability and Disease Prevention, Base for International Science and Technology Cooperation: Carson Cancer Stem Cell Vaccines R&D Center, International Cancer Center, Shenzhen Key Laboratory of Translational Medicine in Oncology, School of Basic Medical Sciences, School of Pharmaceutical Sciences, Medical School; College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, 518035, China.
  • 2 Guangzhou KemRocMed Co., Ltd., Guangzhou, 510320, China.
  • 3 Guangdong Provincial Key Laboratory of Genome Stability and Disease Prevention, Base for International Science and Technology Cooperation: Carson Cancer Stem Cell Vaccines R&D Center, International Cancer Center, Shenzhen Key Laboratory of Translational Medicine in Oncology, School of Basic Medical Sciences, School of Pharmaceutical Sciences, Medical School; College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, 518035, China. lzzhu86@pku.edu.cn.
  • 4 Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., Shenzhen, 518057, China. lzzhu86@pku.edu.cn.
  • 5 Guangdong Provincial Key Laboratory of Genome Stability and Disease Prevention, Base for International Science and Technology Cooperation: Carson Cancer Stem Cell Vaccines R&D Center, International Cancer Center, Shenzhen Key Laboratory of Translational Medicine in Oncology, School of Basic Medical Sciences, School of Pharmaceutical Sciences, Medical School; College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, 518035, China. zouyd@szu.edu.cn.
  • 6 Guangdong Provincial Key Laboratory of New Drug Screening, Guangzhou Key Laboratory of Drug Research for Emerging Virus Prevention and Treatment, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China. xibaomin@smu.edu.cn.
  • 7 Guangdong Provincial Key Laboratory of Genome Stability and Disease Prevention, Base for International Science and Technology Cooperation: Carson Cancer Stem Cell Vaccines R&D Center, International Cancer Center, Shenzhen Key Laboratory of Translational Medicine in Oncology, School of Basic Medical Sciences, School of Pharmaceutical Sciences, Medical School; College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, 518035, China. dzheng@szu.edu.cn.
  • # Contributed equally.
PMID: 41772145 DOI: 10.1038/s41401-025-01744-y
Abstract

Surgery followed by Adjuvant chemoradiation is the standard treatment for glioblastoma multiforme (GBM). Temozolomide (TMZ) is the only first-line chemotherapeutic drug approved by the US Food and Drug Administration for the treatment of GBM. Acquired chemoresistance to TMZ is the primary cause of treatment failure, resulting in recurrence and a poor prognosis. O6-methylguanine DNA Methyltransferase (MGMT) overexpression and loss of function mutations targeting mismatch repair (MMR) are the major mechanisms TMZ-resistance found in GBM cells. In this study we developed a new alkylating agent that could overcome TMZ resistance. We designed a new chloroethylnitrosourea analog HJ03, and demonstrated that HJ03 was more potent than TMZ in inhibiting GBM cell lines U251 (MGMT-, MMR+), U87 (MGMT-, MMR-) and T98G (MGMT+, MMR+) as well as colorectal Cancer cell line HCT116 (MGMT+, MMR-) with MGMT overexpression or MMR dysfunction. Furthermore, HJ03 exerted a dual synergistic attack effect by inducing DNA damage and Ferroptosis in U251, U87 and T98G cells. We showed that HJ03 caused U251 and T98G cells to be arrested in G2/M phase and undergo Apoptosis by inducing the formation of DNA adducts and interstrand crosslinks. In U251, U87 and T98G cells, HJ03 promoted extensive Ferroptosis by upregulating p53 and ATF3 expression while downregulating SLC7A11, leading to intracellular accumulation of ROS and Fe2+ along with increased MDA levels. Pharmacokinetic study showed that HJ03 crossed the blood-brain barrier more efficiently than TMZ and exhibited lower levels of bone marrow toxicity. In model mice bearing orthotopic CT2A GBM tumors, administration of HJ03 (20 mg/kg, i.g. 5 consecutive days per week for 3 weeks) significantly prolonged the lifespan. Furthermore, HJ03 synergized with radiotherapy and an anti-PD-1 monoclonal antibody to dramatically prolong mouse survival. Thus, HJ03 emerges as a promising novel candidate for GBM treatment, particularly for patients with TMZ-resistant tumors.

Keywords

DNA damage; MGMT; chloroethylnitrosourea analog HJ03; ferroptosis; glioma; temozolomide resistance.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z